Why the study?
Does eicosapentaenoic acid added to statin therapy improve atherosclerotic plaque characteristics and reduce cardiovascular events in patients with residual cardiovascular risk?
Population
Patients with residual cardiovascular risk despite optimized statin therapy, including those with coronary…
Comparison
Eicosapentaenoic acid or icosapent ethyl added… vs Statin therapy alone
Design
Review
Authors
Loading...
Supports EPA as a potential adjunct for residual cardiovascular risk; leaves open whether these regional findings translate to broader.
Does eicosapentaenoic acid added to statin therapy improve atherosclerotic plaque characteristics and reduce cardiovascular events in patients with residual cardiovascular risk?
Eicosapentaenoic acid added to statin therapy may reduce residual cardiovascular risk by improving atherosclerotic plaque characteristics and reducing major coronary events.
Nelson et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: